Mastocitose: caracterizada por uma aumento patológico do número de mastócitos em vários tecidos: pele, bone marrow, liver, gastrointestinal, spleen, lymph nodes.
Heterogenous group
Classificação (2008 WHO)
Mastocitose Cutânea | Urticaria pigmentosaMastocitose Sistémica- Age of onset: child or adult
- Location of the disease (cutaneous or systemic)
- Course (indolent or aggressive)
Fisiopatologia
- Mastócitos
- Derivcam de Células CD34+ pluripotentes da medula óssea
- Migram pela corrente sanguínea até aos seus sítios específicos
- Na pele, estão preferencialmente junto a vasos sanguíneos, nervos, folículos pilosos
- Maturam por influencia de citoquinas (IL4, NGF)
- Função
- Papel sentinela, estimulando o sistema imunitário contra parasitas e bactérias
- Promovem a reparação e regeneração tecidular
- Regulam angiogénese, tónus vascular e permeabilidade
- Ativação
- Mecanismos imunológicos e não imunológicos (ver urticária)
- Mediadores libertados
- Mast cell growth factor SCF also stimulates melanocytes → increased pigmentation
Histologia
- Mastócitos têm grânulos metacromáticos que coram com toluidine azul
- KIT membranar (CD117) é o marcador imunohistoquímico muitas vezes usado
DDx
- Disorders that cause a secondary increase in mast cells
- Parasitic infections
- Toxoplasmosis
- Allergic reactions (urticaria, insect bites)
- Immunological reactions (GVHD, granulomatous reactions)
- Benign tumors (hemangioma, neurofibroma)
- Benign hematological disorders (thrombocytopenia, hypereosinophilic syndrome, porphyrias, Castleman’s disease)
- Malignant disorders (Hodgkin’s and other lymphomas)
Exames complementares
- Serum triptase
- Urinary histamine
Tratamento
- Prognosis for mastocytosis in children is almost always favorable. Pigmented urticaria regresses in half of cases around puberty, while congestive manifestations fade around the age of 2 or 3.
- There is currently no cure
- Elimintation of mast cell degranulation factors
- Avoid: general anesthesia, imaging with iodinated contrast agents, medications
- Introduction of drugs that may induce degranulation of mastcells must be carried out under strict medical supervision with paramedication with antihistamines
- General anesthesia without precautions or without information from the anesthesiologist is considered high risk in these patients
- Symptomatic treatment
- Antihistamines
- Proton pump inhibitor if peptic ulcer due to gastric histamine release
- Disodium cromoglycate - mast cell membrane-stabilizer. 800mg/day for adults, 60-100mg/day for children
- Phototherapy
- PUVA, UVA1
- Topical very strong corticosteroids
- Adrenaline if signs of anaphylatic shock
- Biphosphonates for bone pain and osteoporosis
- If aggressive and/or symptomatic
- Tyrosine kinase inhibitors
- Imatinib, masitinib, midostaurin
- Interferon
- Chemptherapies
- Allogenic bone marrow transplant